Olatoyosi Odenike to Leukemia
This is a "connection" page, showing publications Olatoyosi Odenike has written about Leukemia.
Connection Strength
0.662
-
DNA repair genes, electromagnetic fields and susceptibility to acute leukemia? Leuk Lymphoma. 2008 Dec; 49(12):2233-4.
Score: 0.284
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
Score: 0.185
-
Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010 Jan; 10(1):23-36.
Score: 0.077
-
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
Score: 0.068
-
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.
Score: 0.024
-
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013 Sep; 54(9):1989-95.
Score: 0.024